PFKFB3 inhibition dictates the adaptive responses and cell fates in tumor cells.

Authors

Dianpeng Zheng, Yaowen Mao, Zhipeng Ai, Yue Song, Xiaoyu Liu, Ruoqing Xu, Chenyang Ma, Weikang Meng, Feng He, Hongqing Liang, Jun Ma

Published in

iScience. Volume 29. Issue 11. Pages 117768. Nov 20, 2026. Epub Oct 07, 2026.

Abstract

6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a key regulator of glycolysis highly expressed in many tumor cells, has a critical role in promoting glycolysis and tumor progression. Consequently, anti-cancer strategies have sought to inhibit PFKFB3 to exploit this metabolic dependency of tumor cells. In this study, we employed a controlled protein degradation system to manipulate the kinetics of PFKFB3 depletion in investigating its impact on tumor cell growth. We show that, while slow depletion allows metabolic adaptation with a minimal effect on proliferation, rapid depletion or acute inhibition suppresses cell growth despite a similar glycolytic reduction. We show that rapid PFKFB3 loss activates AMPK, which perturbs cell cycle progression through the MAPK/ERK pathway. Importantly, AMPK inhibition was sufficient to rescue the adaptation failure caused by rapid PFKFB3 depletion. Together, our findings document that dynamic targeting of PFKFB3 can drive heterogeneous cancer cell fates, shedding light on cells' potential path toward developing resistance to anti-PFKFB3 treatments.

PMID:
42894543
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.